Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Elevar Therapeutics

    Client Virtual Booth

    ELEVAR THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Elevar Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Oyster Point Blvd, Suite 214 South San Francisco, CA 94080 U.S.A.
    Telephone
    Telephone
    353-1-969-6739
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://elevartherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/elevartherapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study
    Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study

    https://www.globenewswire.com//news-release/2024/01/18/2811566/0/en/Elevar-Therapeutics-To-Present-Two-Posters-From-Phase-3-CARES-310-Study-at-2024-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    18 Jan 2024
    Share Share
    Elevar Therapeutics Names Brian Cunningham Vice President of Sales
    Elevar Therapeutics Names Brian Cunningham Vice President of Sales

    https://www.globenewswire.com//news-release/2023/10/23/2764745/0/en/Elevar-Therapeutics-Names-Brian-Cunningham-Vice-President-of-Sales-and-Kenneth-Rankin-Vice-President-of-Market-Access-Strengthening-Commercial-Leadership-in-Buildup-to-Launch.html

    GLOBENEWSWIRE
    23 Oct 2023
    Share Share
    Hengrui, Elevar strike $600M marketing deal for liver cancer med
    Hengrui, Elevar strike $600M marketing deal for liver cancer med

    https://www.fiercepharma.com/pharma/elevar-ponies-600m-take-hengruis-investigational-liver-cancer-cocktail-market-us-and-beyond

    Fraiser Kansteiner FIERCE PHARMA
    17 Oct 2023
    Share Share
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab

    https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
    Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

    https://www.globenewswire.com//news-release/2023/09/21/2747337/0/en/Elevar-Therapeutics-to-Present-at-Cantor-Fitzgerald-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    21 Sep 2023
    Share Share
    Elevar Therapeutics Joins Benefactors Council of Blue Faery
    Elevar Therapeutics Joins Benefactors Council of Blue Faery

    https://www.globenewswire.com//news-release/2023/09/19/2745689/0/en/Elevar-Therapeutics-Joins-Benefactors-Council-of-Blue-Faery-Leading-Hepatocellular-Carcinoma-Advocacy-Group.html

    GLOBENEWSWIRE
    19 Sep 2023
    Share Share
    Elevar Names Dr. Chris Galloway Vice President of Clinical Development
    Elevar Names Dr. Chris Galloway Vice President of Clinical Development

    https://www.globenewswire.com/news-release/2023/08/15/2725506/0/en/Elevar-Therapeutics-Names-Dr-Chris-Galloway-Vice-President-of-Clinical-Development.html

    GLOBENEWSWIRE
    15 Aug 2023
    Share Share
    Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib
    Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib

    https://www.globenewswire.com/news-release/2023/08/03/2718088/0/en/Elevar-Therapeutics-to-Host-August-10-Virtual-KOL-Event-on-Phase-3-Study-of-Rivoceranib-in-Combination-with-Camrelizumab-in-Unresectable-Hepatocellular-Carcinoma-uHCC.html

    GLOBENEWSWIRE
    03 Aug 2023
    Share Share
    Elevar Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
    Elevar Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

    https://www.globenewswire.com/news-release/2023/07/25/2710043/0/en/Elevar-Therapeutics-Announces-Publication-of-Phase-3-CARES-310-Study-Results-in-The-Lancet.html

    GLOBENEWSWIRE
    24 Jul 2023
    Share Share
    Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
    Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab

    https://www.globenewswire.com/news-release/2023/07/17/2705640/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-for-Filing-of-New-Drug-Application-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Treatment-for-Unresectable-Hepatoce.html

    GLOBENEWSWIRE
    17 Jul 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search